As of 09:44 on November 12, 2024, the Medical Innovation ETF (516820) rose 2.67%, the latest price was 0.38 yuan, and the intraday turnover has reached 24.4838 million yuan. The CSI Pharmaceutical and Medical Device Innovation Index (931484) of the tracking index rose strongly by 2.96%, the constituent stocks of Preh Ophthalmology (301239) rose 7.51%, Shenzhou Cell (688520) rose 7.16%, Yirui Technology (688301) rose 5.36%, Aier Ophthalmology (300015), Zhifei Biotechnology (300122) and other stocks followed suit.

In the long run, as of November 11, 2024, the medical innovation ETF has risen by 6.86% in the past 1 week, ranking 1/2 of comparable funds. In terms of scale, the latest scale of medical innovation ETF reached 1.517 billion yuan, a new high in January, ranking 1/2 of comparable funds. In terms of shares, the share of medical innovation ETFs increased by 194 million in the past 1 month, achieving significant growth, and the new shares ranked 1/2 of comparable funds.

In terms of fund inflow, the latest net inflow of medical innovation ETF was 19.1764 million yuan. In the long run, there have been 13 net inflows of funds in the past 21 trading days, with a total of 67.812 million yuan of "gold absorption", and an average daily net inflow of 3.2291 million yuan.

The data shows that leveraged funds continue to be deployed. The net purchase amount of medical innovation ETF on the previous trading day reached 4.7038 million yuan, and the latest financing balance reached 79.5796 million yuan.

It is worth noting that the valuation of the CSI Pharmaceutical and Medical Device Innovation Index tracked by the fund is at a historical low, with the latest price-to-book ratio of 4.37 times, which is lower than the index of more than 83.42% in the past three years, and the valuation is cost-effective.

On the news side, on November 11, the Office of the National Health Insurance Administration and the General Office of the Ministry of Finance issued a notice on doing a good job in the prepayment of the medical insurance fund.

In this regard, the analysis of industry institutions pointed out that 1. Good drug consumption turnover: The notice makes it clear that the prepayment system is to help designated medical institutions alleviate the pressure of medical expenses, improve medical service capabilities, and enhance the sense of access to medical treatment set up by the working capital, which is used for medical expenses such as the procurement of drugs and medical consumables, and shall not be used for non-medical expenses such as infrastructure investment, daily operation, and debt repayment of medical institutions.

2. Speed up the payment settlement of consumables manufacturers: Hospitals can obtain financial support before providing patients with high-quality medical services, which greatly reduces the financial burden of hospitals. Through the step of pre-funding support, the hospital will be more flexible and active in the allocation of resources, which is conducive to scientific planning of medical resources and improving service efficiency.

3. After the establishment of the medical insurance prepayment system, the pressure on the capital turnover of medical institutions will be greatly alleviated, and the upstream and downstream account periods are expected to improve. Combined with the direct settlement system, the construction of an online settlement platform and other multi-faceted measures, the payment collection cycle is expected to be greatly shortened. The establishment of a medical insurance prepayment system is conducive to reducing the pressure on hospital advances, speeding up the payment cycle of commercial companies, and also conducive to the increase in the volume of prescription drugs and consumables in the hospital.

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of October 31, 2024, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are WuXi AppTec (603259), Aier Ophthalmology (300015), Mindray Medical (300760), United Imaging Healthcare (688271), Kelun Pharmaceutical (002422), Zhifei Biotech (300122), Changchun High-tech (000661), Aimeike (300896), and Pharmaron (300759). ), Huitai Medical (688617), the top ten weighted stocks accounted for 65.19%.

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of October 31, 2024, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are WuXi AppTec (603259), Aier Ophthalmology (300015), Mindray Medical (300760), United Imaging Healthcare (688271), Kelun Pharmaceutical (002422), Zhifei Biotech (300122), Changchun High-tech (000661), Aimeike (300896), and Pharmaron (300759). ), Huitai Medical (688617), the top ten weighted stocks accounted for 65.19%.

See the original image 50K